InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.50
(
0.25%
)
US TECH 100
18,215.00
(
0.10%
)
Dow Jones
39,873.58
(
0.17%
)
Brent Oil
82.76
(
-0.93%
)
Bitcoin
69,251.08
(
-3.08%
)
Post# of 251872
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119666
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bUrRpPPP! post# 250494

Thursday, 04/04/2024 4:49:33 PM

Thursday, April 04, 2024 4:49:33 PM

Post# of 251872
EFTR—(-82%)—reports disastrous phase-2 data for Tomivosertib as addend to Keytruda in first-line NSCLC:

https://finance.yahoo.com/news/effector-therapeutics-announces-topline-results-123000557.html

The two-sided p value for PFS, based on a stratified log rank test, was 0.21, which did not meet the pre-specified threshold… Overall survival results remain immature, however no trend favoring tomivosertib was observed.

There were 67% Grade 3 or higher treatment emergent adverse events in the tomivosertib plus pembrolizumab arm versus 37% in the placebo plus pembrolizumab arm.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up